Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

Tran B, Voskoboynik M, Kim SW, Lemech C, Carcereny E, Rha SY, Ahn MJ, Felip E, Lee KH, Castañón Álvarez E, Yang JC, Ascierto PA, Provencio Pulla M, Kondo S, Kuboki Y, Freeman D, Song X, Blando J, Eck S, Song FJ, Tang Z, Kuziora M, Gainer SD, Mitchell P, Asare J, Ayyoub A, Achour I, Subramaniam DS, Im SA

Open source

DOI: 10.1158/1078-0432.ccr-25-3447
Published: 2026 Jul 17
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-3447,
  title = {Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.},
  author = {Tran B and Voskoboynik M and Kim SW and Lemech C and Carcereny E and Rha SY and Ahn MJ and Felip E and Lee KH and Castañón Álvarez E and Yang JC and Ascierto PA and Provencio Pulla M and Kondo S and Kuboki Y and Freeman D and Song X and Blando J and Eck S and Song FJ and Tang Z and Kuziora M and Gainer SD and Mitchell P and Asare J and Ayyoub A and Achour I and Subramaniam DS and Im SA},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-3447},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-3447}
}

RIS

TY  - JOUR
TI  - Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.
AU  - Tran B
AU  - Voskoboynik M
AU  - Kim SW
AU  - Lemech C
AU  - Carcereny E
AU  - Rha SY
AU  - Ahn MJ
AU  - Felip E
AU  - Lee KH
AU  - Castañón Álvarez E
AU  - Yang JC
AU  - Ascierto PA
AU  - Provencio Pulla M
AU  - Kondo S
AU  - Kuboki Y
AU  - Freeman D
AU  - Song X
AU  - Blando J
AU  - Eck S
AU  - Song FJ
AU  - Tang Z
AU  - Kuziora M
AU  - Gainer SD
AU  - Mitchell P
AU  - Asare J
AU  - Ayyoub A
AU  - Achour I
AU  - Subramaniam DS
AU  - Im SA
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-3447
UR  - https://doi.org/10.1158/1078-0432.ccr-25-3447
ER  -

APA

B, T., M, V., SW, K., C, L., E, C., SY, R., MJ, A., E, F., KH, L., E, C. Á., JC, Y., PA, A., M, P. P., S, K., Y, K., D, F., X, S., J, B., S, E., FJ, S., Z, T., M, K., SD, G., P, M., J, A., A, A., I, A., DS, S., & SA, I. (2026). Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-3447

Source records

pubmed · retrieved 2026-09-27T16:00:42.370Z
europe-pmc · retrieved 2026-09-27T16:00:42.388Z